Trials in Boston, Massachusetts
Here are the top 10 medical studies for lung cancer in Boston, Massachusetts
Popular Filters
Phase 3 Trials
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Tyrosine Kinase Inhibitor
Osimertinib + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial is testing osimertinib, a drug that targets cancer cells, either by itself or with chemotherapy. It focuses on patients with a specific type of lung cancer that has a mutation in the EGFR gene. The drug works by stopping the growth of cancer cells.
Tyrosine Kinase Inhibitor
Osimertinib + Bevacizumab for Lung Cancer
Recruiting2 awardsPhase 3
Winchester, Massachusetts
This trial is testing whether adding bevacizumab to osimertinib will help patients with EGFR-mutated, stage IIIB-IV non-small cell lung cancer live longer, as compared to osimertinib alone.
Trials With No Placebo
Tyrosine Kinase Inhibitor
Cabozantinib + Nivolumab for Lung Cancer
Recruiting1 awardPhase 2
West Haven, Connecticut
This trial is testing whether cabozantinib alone or with nivolumab is better than other treatments for patients with a type of lung cancer called non-squamous non-small cell lung cancer. Cabozantinib stops cancer cells from growing, while nivolumab helps the immune system fight the cancer. The goal is to see if these treatments can help patients live longer without their cancer getting worse.
Tyrosine Kinase Inhibitor
Selpercatinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Hartford, Connecticut
This trial will study how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer. Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Tyrosine Kinase Inhibitor
Osimertinib + Bevacizumab for Lung Cancer
Recruiting2 awardsPhase 3
Winchester, Massachusetts
This trial is testing whether adding bevacizumab to osimertinib will help patients with EGFR-mutated, stage IIIB-IV non-small cell lung cancer live longer, as compared to osimertinib alone.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.